Table 2.
Fluoroquinolones (n = 21) | Azithromycin (n = 20) | P value | |
---|---|---|---|
Clinical Outcomes | |||
Mortality | |||
All patients | 2/21 (9.5%) | 1/20 (5%) | > 0.99 |
ICU patients | 2/10 (20%) | 1/5 (20%) | > 0.99 |
Time to clinical stability* | |||
All patients | 15.89 ± 12.05 | 10.26 ± 6.96 | 0.09 |
ICU patients | 25.3 ± 12.4 | 17.6 ± 6.8 | 0.24 |
Length of hospitalization* | |||
Length of stay for all patients | 19.29 ± 16.62 | 11.35 ± 7.49 | 0.06 |
ICU length of stay | 14.57 ± 8.03 | 11.89 ± 7.15 | 0.42 |
Duration of mechanical ventilation* | 12.79 ± 7.40 | 10.13 ± 7.72 | 0.43 |
Complications | |||
Acute renal failure | 12/21 (57%) | 10/20 (50%) | 0.76 |
Dialysis | 5/21 (24%) | 5/20 (25%) | > 0.99 |
Transaminase elevation | 14/21 (67%) | 11/20 (55%) | 0.53 |
Pleural effusion | 10/21 (48%) | 6/20 (30%) | 0.34 |
Respiratory failure | 17/21 (81%) | 16/20 (80%) | > 0.99 |
Vasopressor use | 7/21 (33%) | 7/20 (35%) | > 0.99 |
mean ± standard deviation